孕期接种BNT162b2新冠疫苗与新生儿及早期婴儿结局的关联
调整混杂因素后,暴露组与非暴露组在早产、小于胎龄儿、先天性畸形、住院及婴儿死亡风险上均无显著差异。
要点
- 孕期接种BNT162b2疫苗未增加早产或小于胎龄儿风险。
- 先天性畸形、全因住院及婴儿死亡风险在暴露组与非暴露组间无显著差异。
- 研究为观察性设计,结果解读需考虑其局限性。
核心结论
- 孕期接种BNT162b2 mRNA疫苗与新生儿及早期婴儿不良结局无显著关联。
研究设计与样本
- 基于人群的队列研究,纳入以色列大型健康组织2021年3月至9月所有单胎活产新生儿,随访至2021年10月31日。
主要发现
- 暴露组与非暴露组早产率无显著差异(RR=0.95;95%CI 0.83-1.10)。
- 小于胎龄儿风险无显著差异(RR=0.97;95%CI 0.87-1.08)。
- 全因新生儿住院风险无显著差异(RR=0.99;95%CI 0.88-1.12)。
- 先天性畸形风险无显著差异(RR=0.69;95%CI 0.44-1.04)。
- 婴儿死亡风险无显著差异(RR=0.84;95%CI 0.43-1.72)。
关键数值与推荐
- 暴露组中2134名在孕早期暴露,9364名在孕中期暴露。
- 使用稳定逆概率加权调整母亲年龄、受孕时间、产次、社会经济地位、人群亚组及母亲流感免疫状态。
临床怎么用
- 可为孕期女性接种BNT162b2 mRNA疫苗的安全性咨询提供观察性证据支持。
局限性
- 研究为观察性设计,结果解读受此限制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Pregnant women were excluded from the BNT162b2 messenger RNA (mRNA) COVID-19 vaccine (Pfizer-BioNTech) preauthorization trial. Therefore, observational data on vaccine safety for prenatally exposed newborns are critical to inform recommendations on maternal immunization. OBJECTIVE: To examine whether BNT162b2 mRNA vaccination during pregnancy is associated with adverse neonatal and early infant outcomes among the newborns. DESIGN, SETTING, AND PARTICIPANTS: Population-based cohort study comprising all singleton live births in March through September 2021, within a large state-mandated health care organization in Israel, followed up until October 31, 2021. EXPOSURE: Maternal BNT162b2 mRNA vaccination during pregnancy. MAIN OUTCOMES AND MEASURES: Risk ratios (RR) of preterm birth, small birth weight for gestational age (SGA), congenital malformations, all-cause hospitalizations, and infant death. Stabilized inverse probability weighting was used to adjust for maternal age, timing of conception, parity, socioeconomic status, population subgroup, and maternal influenza immunization status. RESULTS: The cohort included 24 288 eligible newborns (49% female, 96% born at ≥37 weeks' gestation), of whom 16 697 were exposed (n = 2134 and n = 9364 in the first and second trimesters, respectively) to maternal vaccination in utero. Median (IQR) follow-up after birth was 126 days (76-179) among exposed and 152 days (88-209) among unexposed newborns. No substantial differences were observed in preterm birth rates between exposed and unexposed newborns (RR = 0.95; 95% CI, 0.83-1.10) or SGA (RR = 0.97; 95% CI, 0.87-1.08). No significant differences were observed in the incidence of all-cause neonatal hospitalizations (RR = 0.99; 95% CI, 0.88-1.12), postneonatal hospitalizations after birth (RR = 0.95; 95% CI, 0.84-1.07), congenital anomalies (RR = 0.69; 95% CI, 0.44-1.04), or infant mortality over the study period (RR = 0.84; 95% CI, 0.43-1.72). CONCLUSIONS AND RELEVANCE: This large population-based study found no evident differences between newborns of women who received BNT162b2 mRNA vaccination during pregnancy, vs those of women who were not vaccinated, and contributes to current evidence in establishing the safety of prenatal vaccine exposure to the newborns. Interpretation of study findings is limited by the observational design.
引用
- Goldshtein I, Steinberg DM, Kuint J, et al. Association of BNT162b2 COVID-19 Vaccination During Pregnancy With Neonatal and Early Infant Outcomes. JAMA Pediatr. 2022. PMID: 35142809. doi:10.1001/jamapediatrics.2022.0001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。